SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
390MEDX finally, not that I like or not in any way, took over lead in stock price. Miljenko Zuanic-11/16/2004
389Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Icebrg-11/1/2004
388Abgenix Announces Third Quarter 2004 Financial Results Tuesday October 26, 4:00 mopgcw-10/26/2004
387Abgenix initiated with "neutral weight" - update Thursday, October 21Icebrg-10/22/2004
386I have been very disappointed in crgn- I thought the guy was a genius as i listeMadharry-10/14/2004
385Just hypothetical - I have a few* shares, so I'm not rooting for failure. (nigel bates-10/14/2004
384I concur, and so I like ABGX at these levels. Nigel, do you really think it wiltuck-10/13/2004
383I don't think egf will fail. And I think it should sell reasonably well. Erbrkrw-10/13/2004
382What do y'all mean by failure? Regulatory/clinical or market failure. I thtuck-10/13/2004
381<<<I agree that 'EGF represents a big proportion of the current marrkrw-10/9/2004
380<<potential income lies so far out>> So how is that different from nigel bates-10/7/2004
379Yes, but the potential income lies so far out. Abgenix might not even exist by tIcebrg-10/7/2004
378<i>So it shouldn't really effect the valuation of the stock at this tinigel bates-10/7/2004
377Biannual Shot May Be More Effective Than Oral Weekly Bisphosphonate Peggy Peck Icebrg-10/6/2004
376Breaking Merck's Bones Robert Langreth, 10.04.04, 2:55 PM ET [Some more infIcebrg-10/5/2004
375Some background information (speculations) with regard to AMG 162. Amgen's Icebrg-10/4/2004
374Amgen Investigational Therapy for Bone Loss, AMG 162, Increased Bone Mineral DenIcebrg-10/4/2004
373Abgenix Announces Positive Clinical Trial Results for ABX10241 Antibody Product Icebrg-10/3/2004
372Abgenix initiated with "buy" Wednesday, September 22, 2004 11:36:35 PIcebrg-9/22/2004
371Erik: Makes sense in that light. My comment was from my usual optimistic outlookfred hayes-9/17/2004
370<<It is of course better than nothing, but not by much.>>> Dollarkrw-9/17/2004
369Fred, my comment was made in the light of the expense rate at which Abgenix presIcebrg-9/17/2004
368>>Providing they didn't get CAT's lawyers to draw up the license akeokalani'nui-9/16/2004
367Erik: But it all goes right to the bottom line. At $50 million, that's > fred hayes-9/16/2004
366>>that represents very material earnings potential.>> Provided the Icebrg-9/16/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News